G protein-coupled receptor
D2 receptor
Dopamine D2 receptor
- GeneDRD2
- FamilyDopamine receptors
- GroupD2-like dopamine receptors
The human D2 receptor was cloned from the pituitary. A single gene gives rise to two splice variants, a longer and a shorter form, which differ by 29 amino acids in the third intracellular loop. These amino acids are encoded by a separate exon, and mRNA for both forms is found in the pituitary and brain of both rats and humans.1,2,3 It belongs to the D2-class dopamine receptors together with the D3 and D4 receptors. These couple to Gi/o proteins and so inhibit adenylyl cyclase, and they also activate potassium channels. The gene for the D2 receptor has six introns, whereas the genes of the D1 and D5 receptors have none.4,5 The two splice forms have different roles. The short form, D2S, is mostly presynaptic and takes part in the autoreceptor functions, while the long form, D2L, is predominantly postsynaptic.4
The highest levels of D2 receptors are found in the striatum, the nucleus accumbens and the olfactory tubercle. They are also expressed at significant levels in the substantia nigra, the ventral tegmental area, the hypothalamus, cortical areas, the septum, the amygdala and the hippocampus.4 In postmortem human brain, autoradiography with the agonist CV 205-502 and the antagonist spiroperidol gave very similar patterns. The highest densities were in the caudate nucleus, the putamen, the nucleus accumbens and the olfactory tubercle, followed by the substantia nigra, where the receptors were mainly in the pars compacta. Densities were lower in the lateral globus pallidus and in the CA1 and CA3 fields of the hippocampus, low in the medial globus pallidus, the dentate gyrus and the amygdala, and almost negligible in most of the neocortex, the cerebellum and the brainstem.6
Antipsychotic drugs block the binding of dopamine and haloperidol in the striatum, and how strongly they block it follows their clinical potency against schizophrenia. This held for the antipsychotics tested.7,8 Essentially all clinically effective antipsychotics can block D2 receptors, which indicates that the receptor plays a critical role in the psychotic reactions of schizophrenia and bipolar disorder.4 PET scans of patients showed that classic antipsychotics at usual doses occupied 70 to 89 percent of D2 receptors, and that patients with acute movement side effects had higher occupancies. Clozapine occupied fewer, 38 to 63 percent.9 In a double-blind study, 22 patients with a first episode of schizophrenia received 1.0 or 2.5 mg of haloperidol a day, and the occupancy of D2 receptors, measured with raclopride and PET after two weeks, ranged from 38 to 87 percent. The likelihood of a clinical response, of raised prolactin and of extrapyramidal side effects rose significantly once the occupancy exceeded 65, 72 and 78 percent.10
A review proposes that atypical antipsychotics differ from the older ones because they dissociate faster from the D2 receptor. According to the authors, this allows an antipsychotic effect without motor side effects, prolactin elevation or secondary negative symptoms. They argue that freedom from motor side effects results from low D2 occupancy and not from high 5-HT2 occupancy, and they set their view against the hypotheses that need several receptors.11 Quetiapine at 300 to 600 mg a day showed an occupancy of less than 20 percent 12 hours after a dose, but occupancies in the 60 percent range after 2 hours, which fits a fast decline of the occupancy.11
Dopamine plays a pivotal role in the regulation of prolactin, which is made by the lactotroph cells of the anterior pituitary. The raised prolactin under antipsychotics correlates mostly with their affinity for D2 receptors at these cells. The highest rates of hyperprolactinaemia are reported for amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favourable profile. All second-generation antipsychotics can raise prolactin, especially at the beginning of treatment.12
Mice without D2 receptors are akinetic and slow and move less on their own, which resembles Parkinson's disease.13
Sources (13)
- Dal Toso et al. 1989Dal Toso R, Sommer B, Ewert M, et al. (1989) The dopamine D2 receptor: two molecular forms generated by alternative splicing EMBO J
- Grandy et al. 1989Grandy DK, Marchionni MA, Makam H, et al. (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor Proc Natl Acad Sci U S A
- Giros et al. 1989Giros B, Sokoloff P, Martres MP, et al. (1989) Alternative splicing directs the expression of two D2 dopamine receptor isoforms Nature
- Beaulieu et al. 2011Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors Pharmacol Rev
- Missale et al. 1998Missale C, Nash SR, Robinson SW, et al. (1998) Dopamine receptors: from structure to function Physiol Rev
- Camps et al. 1989Camps M, Cortés R, Gueye B, et al. (1989) Dopamine receptors in human brain: autoradiographic distribution of D2 sites Neuroscience
- Seeman et al. 1975Seeman P, Chau-Wong M, Tedesco J, et al. (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays Proc Natl Acad Sci U S A
- Seeman et al. 1976Seeman P, Lee T, Chau-Wong M, et al. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors Nature
- Farde et al. 1992Farde L, Nordström AL, Wiesel FA, et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch Gen Psychiatry
- Kapur et al. 2000Kapur S, Zipursky R, Jones C, et al. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am J Psychiatry
- Kapur et al. 2001Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis Am J Psychiatry
- Peuskens et al. 2014Peuskens J, Pani L, Detraux J, et al. (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review CNS Drugs
- Baik et al. 1995Baik JH, Picetti R, Saiardi A, et al. (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors Nature
Binding affinity (Kᵢ)
15 substances, 17 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.
Human
14 measurements
LSD39 nMJanowsky et al. 2014 · 2 reports
- Assay
- HEK cells expressing recombinant human D2; [3H]YM-09151-2 competition binding
- Shown value from
- Janowsky et al. 2014, Table 5
- Range
- 39–200 nM in 2 reports
- Error
- ± 1.8 SEM
This is the best-supported value. Other reports differ. 4 reports in all, 25–200 nM.
Sources and values behind the range, same assay family Report Value Where Jain et al. 2025 200 nM Table S4 Janowsky et al. 2014 39 nM Table 5 ETH-LAD160 nMJain et al. 2025
- Assay
- radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
- Shown value from
- Jain et al. 2025, Table S4
AL-LAD270 nMJain et al. 2025
- Assay
- radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
- Shown value from
- Jain et al. 2025, Table S4
Mescaline300 nMJain et al. 2025
- Assay
- radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
- Shown value from
- Jain et al. 2025, Table S4
2C-C2100 nMRickli et al. 2015
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 400 SD
2C-B2200 nMRickli et al. 2015 · 2 reports
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Range
- 2200–3371 nM in 2 reports
- Error
- ± 300 SD
Sources and values behind the range, same assay family Report Value Where Ray 2010 3371 nM Table S2 (AllKiData) Rickli et al. 2015 2200 nM Table 2 2C-P2300 nMRickli et al. 2015
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 700 SD
2C-I2700 nMRickli et al. 2015
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 580 SD
DMT3000 nMRickli et al. 2016
- Assay
- HEK293 membranes expressing human D2; [3H]spiperone displacement
- Shown value from
- Rickli et al. 2016, Table 2
- Error
- ± 400 SD
2C-E3200 nMRickli et al. 2015 · 2 reports
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Range
- 3200–3339 nM in 2 reports
- Error
- ± 1000 SD
Sources and values behind the range, same assay family Report Value Where Ray 2010 3339 nM Table S2 (AllKiData) Rickli et al. 2015 3200 nM Table 2 Psilocin3700 nMRickli et al. 2016 · 2 reports
- Assay
- HEK293 membranes expressing human D2; [3H]spiperone displacement
- Shown value from
- Rickli et al. 2016, Table 2
- Range
- 2300–3700 nM in 2 reports
- Error
- ± 600 SD
Sources and values behind the range, same assay family Report Value Where Rickli et al. 2016 3700 nM Table 2 Jain et al. 2025 2300 nM Table S4 4-HO-MET4000 nMRickli et al. 2016
- Assay
- HEK293 membranes expressing human D2; [3H]spiperone displacement
- Shown value from
- Rickli et al. 2016, Table 2
- Error
- ± 200 SD
2C-D7100 nMRickli et al. 2015
- Assay
- cloned human receptor (HEK293)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 1700 SD
Rat
1 measurement
ETH-LAD4.4 nMHoffman et al. 1985
- Assay
- rat striatal homogenate; [3H]spiperone competition
- Shown value from
- Hoffman et al. 1985, Part III introduction
Unspecified
2 measurements
LSD155 nMPaulke et al. 2013 · 2 reports
- Assay
- long D2 receptor binding assay; pKi converted to Ki
- Shown value from
- Paulke et al. 2013, Table 2
- Range
- 25–155 nM in 2 reports
Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 25–155 nM.
LSA891 nMPaulke et al. 2013 · 2 reports
- Assay
- long D2 receptor binding assay; pKi converted to Ki
- Shown value from
- Paulke et al. 2013, Table 2
- Range
- 145–891 nM in 2 reports
Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 145–891 nM.
Functional potency (EC₅₀)
6 substances, 11 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
5 measurements
Dizocilpine8.0 nMSeeman et al. 2005
- Assay
- cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
- Shown value from
- Seeman et al. 2005, Results, Figure 2
LSD40 nMSeeman et al. 2005
- Assay
- cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
- Shown value from
- Seeman et al. 2005, Results (data not shown in the figure)
- Emax
- 80.0%
Salvinorin A48 nMSeeman et al. 2009
- Assay
- cloned human D2Long receptors, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 4.0 SEM
- Emax
- 62.0 ± 4.0%
Ketamine110 nMSeeman et al. 2005 · 2 reports
- Assay
- cloned human D2Long in CHO cells, [35S]GTPgammaS incorporation
- Shown value from
- Seeman et al. 2005, Results, Figure 2
- Range
- 110–900 nM in 2 reports
Reported values disagree and no value is established. 2 reports in all, 110–900 nM.
Sources and values behind the range, same assay family Report Value Where Kapur et al. 2002 900 nM Results, Figure 4 Seeman et al. 2005 110 nM Results, Figure 2 PCP144 nMSeeman et al. 2009 · 3 reports
- Assay
- postmortem human striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Range
- 90–4000 nM in 3 reports
- Error
- ± 71 SEM
- Emax
- 49.0 ± 4.7%
Reported values disagree and no value is established. 3 reports in all, 90–4000 nM.
Sources and values behind the range, same assay family Report Value Where Seeman et al. 2009 144 nM Table I Kapur et al. 2002 4000 nM Results, Figure 4 Seeman et al. 2005 90 nM Results, Figure 2
Rat
6 measurements
PCP70 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 30 SEM
- Emax
- 46.0 ± 4.0%
Salvinorin A89 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 11 SEM
- Emax
- 44.0 ± 2.0%
3-HO-PCP103 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 9.0 SEM
- Emax
- 36.0 ± 5.0%
LSD105 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 36 SEM
- Emax
- 36.0 ± 3.0%
Dizocilpine710 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 190 SEM
- Emax
- 29.0 ± 6.0%
Ketamine1033 nMSeeman et al. 2009
- Assay
- rat striatal homogenates, [35S]GTPgammaS incorporation, % of 10 µM dopamine
- Shown value from
- Seeman et al. 2009, Table I
- Error
- ± 329 SEM
- Emax
- 27.0 ± 3.0%
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.